Format

Send to

Choose Destination
Diabetes Metab. 2018 Oct 23. pii: S1262-3636(18)30196-4. doi: 10.1016/j.diabet.2018.10.002. [Epub ahead of print]

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Author information

1
McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: Jean-francois.yale@mcgill.ca.
2
Brigham, Women's Hospital, Endocrinology Division, Boston, MA, USA.
3
Nantes University, Nantes, France.
4
Foundation for Diabetes Research in Older People, Diabetes Frail Ltd, Worcestershire, UK.
5
Hospital de la Ribera, Alzira, Spain.
6
The Diabetes Unit, Endocrinology, Metabolism Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.
7
IVIDATA, Levallois-Perret, France.
8
Sanofi, Paris, France.
9
University of Perugia, Perugia, Italy.
10
Klinikum Schwabing, Städtisches Klinikum München GmbH, Munich, Germany.

Abstract

AIM:

Older people with type 2 diabetes (T2DM) are at an increased risk of hypoglycaemia and its consequences. However, efficacy and safety data for basal insulin therapy are limited in these individuals. This patient-level meta-analysis assessed the treatment effects of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with T2DM ≥ 65 years old.

METHODS:

Data were pooled for patients randomised to receive Gla-300 or Gla-100 in the Phase 3a, treat-to-target EDITION 1, 2 and 3 trials. Glycaemic efficacy, hypoglycaemia, changes in body weight and insulin dosage and adverse events were examined over 6 months' treatment with Gla-300 versus Gla-100 for participants aged ≥ 65 and < 65 years.

RESULTS:

Of 2496 participants randomised, 662 were ≥ 65 years (Gla-300, n = 329; Gla-100, n = 333). Glycaemic control was comparable for Gla-300 and Gla-100 in participants ≥ 65 years (LS mean [95% CI] difference in HbA1c change from baseline to month 6: 0.00 [-0.14 to 0.15] %; 0.00 [-1.53 to 1.64] mmol/mol) and < 65 years (0.00 [-0.09 to 0.08] %; 0.00 [-0.98 to 0.87] mmol/mol). Fewer participants receiving Gla-300 versus Gla-100 experienced nocturnal confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycaemia (relative risk: ≥ 65 years: 0.70 [0.57 to 0.85]; < 65 years: 0.77 [0.68 to 0.87]). Annualised rates of nocturnal confirmed or severe hypoglycaemia were lower with Gla-300 than Gla-100 for both age groups.

CONCLUSION:

Gla-300 was associated with a reduced risk of nocturnal hypoglycaemia versus Gla-100, accompanied by comparable glycaemic improvement, for people aged ≥ 65 and < 65 years with T2DM.

KEYWORDS:

Basal insulin analogues; Glycaemic control; Hypoglycaemia; Meta-analysis; Older individuals; Type 2 diabetes

PMID:
30366067
DOI:
10.1016/j.diabet.2018.10.002
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center